Bioventus (BVS) CFO nets shares after RSU vesting and tax withholding

Rhea-AI Filing Summary

Bioventus Inc. SVP & CFO Mark Leonard Singleton reported RSU vesting and related share movements. On February 15, 2026, 20,153 Restricted Stock Units were converted into 20,153 shares of Class A common stock at $0.00 per share.

Each RSU represents a right to receive one share of Class A common stock. To cover tax obligations, 9,429 Class A shares were disposed of at $8.27 per share in a tax-withholding transaction. After these transactions, Singleton directly owned 151,812 shares of Class A common stock and 40,304 RSUs, subject to time-based vesting conditions tied to continued service.

Insider Trade Summary

20,153 shares exercised/converted

Mixed 3 txns

Insider Singleton Mark Leonard

Role SVP & CFO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	20,153	$0.00	--
Exercise	Class A Common Stock	20,153	$0.00	--
Tax Withholding	Class A Common Stock	9,429	$8.27	$78K

Holdings After Transaction: Restricted Stock Units — 40,304 shares (Direct); Class A Common Stock — 161,241 shares (Direct)

Footnotes (1)

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. The RSUs vest in four approximately equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Singleton Mark Leonard

(Last) (First) (Middle)

4721 EMPEROR BOULEVARD, SUITE 100

(Street)

DURHAM NC 27703

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bioventus Inc. [ BVS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
02/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/15/2026		M		20,153	A	$0	161,241	D
Class A Common Stock	02/15/2026		F		9,429	D	$8.27	151,812	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/15/2026		M			20,153	(2)	(2)	Class A Common Stock	20,153	$0	40,304	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.

2. The RSUs vest in four approximately equal installments on each of the first four anniversaries of February 15, 2024, in each case subject to the Reporting Person continuing in service through the applicable vesting date.

Remarks:

	/s/ Anthony D'Adamio, Attorney-in-Fact	02/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Bioventus (BVS) report for its CFO?

Bioventus reported that its SVP & CFO Mark Leonard Singleton had 20,153 RSUs convert into Class A common shares, then 9,429 shares were disposed of to satisfy tax withholding. These were scheduled equity award events, not open-market stock purchases or sales.

How many Bioventus (BVS) shares does the CFO hold after this Form 4?

After the reported transactions, the Bioventus SVP & CFO directly owned 151,812 shares of Class A common stock. He also held 40,304 Restricted Stock Units, which may convert into additional shares over time if service-based vesting conditions are met.

What triggered the RSU conversion reported in Bioventus (BVS) Form 4?

The Form 4 shows Restricted Stock Units converting into Class A common stock as part of scheduled vesting. The RSUs vest in four approximately equal installments on each of the first four anniversaries of February 15, 2024, contingent on continued service.

Was the Bioventus (BVS) CFO’s share disposition an open-market sale?

No, the 9,429-share disposition was reported under code “F,” meaning shares were delivered to satisfy tax obligations. This is a tax-withholding disposition related to equity vesting, not a discretionary open-market stock sale by the executive.

How do Bioventus (BVS) RSUs work for the CFO’s award?

Each Bioventus Restricted Stock Unit represents a contingent right to receive one share of Class A common stock. The RSUs vest in four approximately equal annual installments starting February 15, 2024, subject to the executive remaining in service through each vesting date.